




[12] Patent

[11] Patent No.: GC 0000142	Number of the Decision to Grant the Patent: 5/207
[45] Date of Publishing the Grant of the Patent: 29/06/2005 4/2005	Date of the Decision to Grant the Patent: 15/03/2005
[21] Application No.: GCC/P/2000/972 [22] Filing Date: 25/10/2000 [30] Priority: [31] Priority No. [32] Priority date [33] State 9925470.8 27/10/1999 GB [72] Inventors: 1- Andrew Faller, 2- John Gerard Ward [73] Owner: Smithkline Beecham P.L.C., New Horizons Court, Brentford, Middlesex TW8 9EP, GB [74] Agent: Suleiman Ibrahim Al-Ammar	[51] Int. Cl. ⁷ : C07C 259/06, 237/22; A61K 31/16; A61P 37/00 [56] Cited Documents: - WO 9967201 A (SMITHKINE BEECHAM) 29 December 1999 - WO 9702239 A (BRITISH BIOTECH PHARMACEUTICALS) 23 January 1997

[54] AN INHIBITOR OF THE FORMATION OF SOLUBLE HUMAN CD23

[57] Abstract: A compound of formula (I):



wherein:

R isopropyl;

n is 0;

R¹ is naphthylmethyl;

R² is t-butyl; and

R³ is methyl;

is useful in the treatment of disorders mediated by s-CD23.

No. of claims: 7